New Market Research Report: OpportunityAnalyzer: Sepsis - Opportunity Analysis and Forecasts to 2021

Sepsis patients suffer from a series of diverse complications arising from the presence of pathogens and/or their toxins in the blood or tissues, which cause a rapidly progressing hyperactive host immune response and cellular dysfunction leading to mortality rates near 50% depending on disease severity. The syndrome places a major burden on the national healthcare systems of the global marketplace, which for the purposes of this report is comprised of the US, France, Germany, Italy, Spain, and the UK. There are currently no marketed drugs to treat sepsis and current treatment options are limited to careful monitoring, pathogen-targeting therapies, and supportive care and symptom management.

For the purposes of this report, GlobalData defines the sepsis market to include sales of sepsis-specific, host-directed products in patients 18 years and older. Therefore a detailed analysis and sales projections for antibiotics is beyond the scope of this report. The projection of annual sales for medical devices is also beyond the scope of this report, however anticipated launch dates and patient uptake estimates for these products is included in the forecast. GlobalData expects the market to experience modest growth that is primarily driven by the increased uptake of novel therapies - led by Asahi Kasei Pharma America Corporation’s ART-123 - in select patients as the critical care community regains confidence in sepsis-specific products and as more data is generated on their overall efficacy and safety. Primary research revealed that skepticism, cynicism, and cautious optimism towards sepsis pipeline products is related to recent high profile failures of products in clinical development.

Full Report Details at
- http://www.fastmr.com/prod/1002596_opportunityanalyzer_sepsis.aspx?afid=301

Highlights

Key Questions Answered

* Based on interviews with key opinion leaders (KOLs), GlobalData has identified the major unmet needs in the sepsis marketplace. Will the leading pipeline agents fulfil these unmet needs during the forecast period (2016-2021)?
* What research and development (R&D) strategies will companies leverage to compete in the future sepsis marketplace?
* Which patient population(s) are most likely to be targeted for sepsis-specific product development?
* What clinical and commercial factors are likely to influence sepsis product uptake in the US and 5EU (France, Germany, Italy, Spain, and the UK)?

Key Findings

* GlobalData projects the sepsis market in the US and 5EU to grow from approximately $26m in 2016 to $354m in 2021, at a compound annual growth rate (CAGR) of 69%. This solid growth will be driven by the increased uptake of novel therapies - led by AKP’s anticoagulant ART-123 - in select patients as the critical care community regains confidence in sepsis-specific products and more data is generated on their overall efficacy and safety.

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156 (1.413.485.7001 Int'l)

You may also be interested in these related reports:

- OpportunityAnalyzer: Graft-Versus-Host Disease - Opportunity Analysis and Forecasts to 2018
- OpportunityAnalyzer: Allergic Conjunctivitis - Opportunity Analysis and Forecasts to 2018
- OpportunityAnalyzer: Chronic Lymphocytic Leukemia - Opportunity Analysis and Forecasts to 2018
- OpportunityAnalyzer: Acne Vulgaris - Opportunity Analysis and Forecasts to 2018
- OpportunityAnalyzer: Dengue Vaccines - Opportunity Analysis and Forecasts to 2020